Mario R Caruso1, Lohit Garg1, Matthew W Martinez2,3. 1. Department of Cardiovascular Medicine, Lehigh Valley Health Network, Allentown, PA, 18103, USA. 2. Department of Cardiovascular Medicine, Atlantic Health, Morristown Medical Center, Morristown, NJ, 07960, USA. Matthew.martinez@atlantichealth.org. 3. Sports Cardiology and Hypertrophic Cardiomyopathy, 111 S Madison Ave, Suite 300, Morristown, NJ, 07960, USA. Matthew.martinez@atlantichealth.org.
Abstract
PURPOSE OF THE REVIEW: This review will explore frequently encountered diagnostic challenges and summarize the role cardiac imaging plays in defining the boundaries of what constitutes the athlete's heart syndrome versus pathology. RECENT FINDINGS: Investigations have predominantly focused on differentiating the athlete's heart from potentially lethal pathological conditions that may produce a similar cardiac morphology. Guidelines have identified criteria for identifying definitive pathology, but difficulty arises when individuals fall in the gray zone of expected athletic remodeling and pathology. Transthoracic echo has traditionally been the imaging modality of choice utilizing parameters such as wall thickness, wall:volume ratio, and certain diastolic parameters. Newer echocardiogram techniques such as strain imaging and speckle tracking have potential additive utility but still need further investigation. Cardiac magnetic resonance (CMR) imaging has emerged as an additive technique to help differentiate the phenotypic overlap between these groups. Utilizing gadolinium enhancement and T1 mapping along with its excellent spatial resolution can help distinguish pathology from physiology. Both established and novel cardiac imaging modalities have been used for uncovering the at risk athletes with cardiomyopathies. The issue is of practical importance because athletes are frequently referred to the cardiologist with symptoms of fatigue, palpitations, presyncope, and/or syncope concerned about the safety of their future participation. Imaging is a key component of risk stratification and identifying normal findings of the developed athlete and those "at-risk" athletes.
PURPOSE OF THE REVIEW: This review will explore frequently encountered diagnostic challenges and summarize the role cardiac imaging plays in defining the boundaries of what constitutes the athlete's heart syndrome versus pathology. RECENT FINDINGS: Investigations have predominantly focused on differentiating the athlete's heart from potentially lethal pathological conditions that may produce a similar cardiac morphology. Guidelines have identified criteria for identifying definitive pathology, but difficulty arises when individuals fall in the gray zone of expected athletic remodeling and pathology. Transthoracic echo has traditionally been the imaging modality of choice utilizing parameters such as wall thickness, wall:volume ratio, and certain diastolic parameters. Newer echocardiogram techniques such as strain imaging and speckle tracking have potential additive utility but still need further investigation. Cardiac magnetic resonance (CMR) imaging has emerged as an additive technique to help differentiate the phenotypic overlap between these groups. Utilizing gadolinium enhancement and T1 mapping along with its excellent spatial resolution can help distinguish pathology from physiology. Both established and novel cardiac imaging modalities have been used for uncovering the at risk athletes with cardiomyopathies. The issue is of practical importance because athletes are frequently referred to the cardiologist with symptoms of fatigue, palpitations, presyncope, and/or syncope concerned about the safety of their future participation. Imaging is a key component of risk stratification and identifying normal findings of the developed athlete and those "at-risk" athletes.
Entities:
Keywords:
Athlete’s heart; Cardiac imaging; Gray zone
Authors: Michael Scharf; Matthias H Brem; Matthias Wilhelm; U Joseph Schoepf; Michael Uder; Michael M Lell Journal: Radiology Date: 2010-08-31 Impact factor: 11.105
Authors: W Gregory Hundley; David A Bluemke; J Paul Finn; Scott D Flamm; Mark A Fogel; Matthias G Friedrich; Vincent B Ho; Michael Jerosch-Herold; Christopher M Kramer; Warren J Manning; Manesh Patel; Gerald M Pohost; Arthur E Stillman; Richard D White; Pamela K Woodard Journal: J Am Coll Cardiol Date: 2010-06-08 Impact factor: 24.094
Authors: Steffen E Petersen; Joseph B Selvanayagam; Jane M Francis; Saul G Myerson; Frank Wiesmann; Matthew D Robson; Ingegerd Ostman-Smith; Barbara Casadei; Hugh Watkins; Stefan Neubauer Journal: J Cardiovasc Magn Reson Date: 2005 Impact factor: 5.364
Authors: Antonio Pelliccia; Barry J Maron; Rosanna De Luca; Fernando M Di Paolo; Antonio Spataro; Franco Culasso Journal: Circulation Date: 2002-02-26 Impact factor: 29.690
Authors: Deirdre F Waterhouse; Tevfik F Ismail; Sanjay K Prasad; Mathew G Wilson; Rory O'Hanlon Journal: Br J Sports Med Date: 2012-11 Impact factor: 13.800
Authors: Marco Fogante; Giacomo Agliata; Maria Chiara Basile; Paolo Compagnucci; Giovanni Volpato; Umberto Falanga; Giulia Stronati; Federico Guerra; Davide Vignale; Antonio Esposito; Antonio Dello Russo; Michela Casella; Andrea Giovagnoni Journal: Medicina (Kaunas) Date: 2021-05-07 Impact factor: 2.430